Subtotal $0.00
- info@pharmoss.org
- 1st Floor, B-10, Block 16, WCHS, KDA Scheme No.24, Karachi
For decades, pharmaceutical marketing has focused heavily on reach: more field visits, more interactions, more events and more opportunities to place a brand message in front of healthcare professionals but HCP engagement in Pakistan is evolving. Healthcare professionals today have access to more scientific information, digital platforms and independent information sources than ever before. At the same time, pharmaceutical companies face increasing pressure to make every HCP interaction more relevant, credible and measurable.
The conversation is therefore shifting from:
“How many HCPs did we reach?” to: “Did we reach the right HCP, with the right information, at the right time — and did the interaction create value?”
This shift from reach to relevance could shape the next phase of pharmaceutical marketing and healthcare professional engagement in Pakistan. Pakistan’s 2026 National Conference on Pharma Marketing reflected many of these themes, with discussions around science, technology, trust, artificial intelligence, digital transformation and evolving customer-engagement models.
Traditional pharmaceutical field engagement is unlikely to disappear. Face-to-face interaction remains valuable, particularly when meaningful scientific discussion and professional relationships are involved.
What is changing is what healthcare professionals expect from those interactions.
Globally, HCPs are increasingly using digital tools and artificial intelligence to access medical information. A large 2026 IQVIA study across 34 markets found that 80% of surveyed physicians were using at least one AI tool, with almost half using AI daily or several times a week. IQVIA
This does not mean AI replaces pharmaceutical engagement. It means the bar for engagement becomes higher. By the time an HCP interacts with a pharmaceutical representative, attends a scientific session or joins a digital engagement, they may already have researched the disease area, treatment options or available evidence. The value of the interaction therefore increasingly depends on relevance, scientific credibility, accessibility and context.
For pharmaceutical companies in Pakistan, this means HCP engagement strategies need to move beyond contact frequency and focus more strongly on understanding the healthcare professional behind the contact.
Reaching thousands of healthcare professionals may look impressive on a dashboard.
But reach alone does not tell us:
Effective healthcare professional engagement in Pakistan increasingly requires better segmentation. Instead of treating HCPs as one broad audience, pharmaceutical organizations can consider variables such as:
Specialty
Practice setting
Patient profile
Geography
Clinical interests
Information needs
Digital behaviour
Current perceptions
Engagement preferences
This is where market research becomes an important part of HCP strategy. Through physician, HCP and KOL research, companies can better understand prescribing behaviour, clinical decision drivers, evidence needs, brand perceptions and barriers to adoption.
PharmOSS’s Market Research & Insights services support healthcare and pharmaceutical organizations with physician/HCP research, KOL research, patient insights, treatment-pathway studies, product-adoption research and other market-intelligence requirements.
One of the biggest mistakes in pharmaceutical marketing is developing an engagement campaign before understanding the audience. Before deciding how to engage HCPs, organizations should first understand:
What information do they actually need?
What barriers influence prescribing or recommendation?
How do HCP perceptions differ by specialty or geography?
What questions remain unanswered about the product or therapeutic area?
Which engagement formats provide genuine value?
What influences product consideration or adoption?
These questions can be explored through quantitative and qualitative pharmaceutical market research.
Methods may include:
The purpose is not to collect data for the sake of research. It is to build HCP engagement strategies based on evidence rather than assumptions.
Healthcare professionals are constantly exposed to information. Adding more promotional messages does not necessarily increase engagement. The question pharmaceutical marketers should ask is:
The answer increasingly lies in providing meaningful professional or scientific value.
That could involve:
This is especially important as HCPs become more capable of independently accessing medical information.
IQVIA has described AI as increasingly becoming a “front door” to medical information, with clinicians using AI-enabled tools to find and interpret scientific information before some traditional pharmaceutical interactions occur.
For pharmaceutical companies, that means the future of HCP marketing may depend less on simply delivering information and more on providing relevant interpretation, context and meaningful engagement around that information.
The future of HCP engagement in Pakistan is unlikely to be completely physical or completely digital. It will increasingly be a combination of both.
A healthcare professional might:
discover information digitally → attend a scientific session → speak with a field representative → receive additional educational content → participate in a workshop → provide feedback.
Each interaction becomes part of a broader HCP journey. This is why organizations should think beyond individual channels and consider the overall engagement experience.
Digital HCP engagement can include:
Physical engagement may include:
The objective should not be to use every available channel. It should be to identify the right combination of channels for the right audience.
HCP engagement should not operate in isolation from market access. A physician might understand a product and recognize its clinical relevance, but adoption may still be affected by:
This is why successful pharmaceutical commercialization requires a broader view.
HCP awareness + patient access + distribution + market positioning + stakeholder engagement must work together.
For companies introducing new pharmaceuticals, vaccines, diagnostics, medical devices or other healthcare products in Pakistan, engagement should therefore be connected to the wider market-access strategy.
Not every HCP engagement needs to be a conventional presentation. Healthcare professional engagement can become more interactive through:
The goal should be participation rather than passive attendance.
PharmOSS’s Experiential Marketing services include pharmaceutical programs, scientific engagement, HCP activities, events and activation programs designed to create structured professional interaction. When appropriate, combining scientific education with experiential engagement can make professional programs more useful, interactive and memorable.
The next generation of pharmaceutical engagement is likely to be less about maximum reach and more about maximum relevance. Successful organizations will increasingly need to understand:
That requires closer integration between market research, HCP insights, scientific engagement, market access, capability building and on-ground execution. PharmOSS supports pharmaceutical and healthcare organizations across these areas through its integrated Pharma & FMCG solutions, combining market understanding with stakeholder engagement and implementation capabilities. pharmoss.org
PharmOSS supports pharmaceutical and healthcare organizations in developing structured, insight-led approaches to HCP engagement in Pakistan.
Depending on project requirements, support can include:
HCP and KOL research, HCP mapping and segmentation, Stakeholder insights, Scientific engagement programs, Healthcare professional workshops, Training and capacity building, Market-access stakeholder engagement, Experiential healthcare programs, Field coordination, Feedback collection and Monitoring and reporting
Explore PharmOSS’s Market Research & Insights, Market Access and Experiential Marketing capabilities to develop an approach aligned with your healthcare or pharmaceutical objectives.
HCP engagement refers to the ways pharmaceutical and healthcare organizations interact with healthcare professionals through scientific communication, professional education, field engagement, digital channels, research, workshops and other relevant activities.
Effective HCP engagement in Pakistan can help pharmaceutical organizations better understand healthcare-professional needs, improve scientific communication, identify barriers to product adoption and support broader commercialization and market-access strategies.
Companies can improve HCP engagement by using HCP research and segmentation, delivering relevant scientific content, selecting appropriate engagement channels, gathering feedback and measuring the quality and outcomes of interactions rather than focusing only on reach.
Digital HCP engagement involves interacting with healthcare professionals through channels such as webinars, virtual scientific sessions, online educational content, digital communication, surveys and professional-learning platforms.
HCP research can identify prescribing drivers, treatment behaviours, evidence needs, perceptions, adoption barriers and engagement preferences. These insights can support pharmaceutical marketing, product launches, market access and communication strategies.
Yes. PharmOSS supports healthcare and pharmaceutical organizations through HCP and KOL research, stakeholder engagement, scientific programs, professional training, experiential activities, field coordination and related implementation support.